AU · rank #2 · 2026-09-09
PGEN
NASDAQ · $2.46B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 2.983 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.48 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) $24,662 across 1 unique buyers. | 3.000 |
| Analyst upside Consensus target $14.50 | +111.1% |
| Momentum acceleration 3-month minus 12-month momentum. | +35.07% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 3.75 |
| Gross margin TTM | +53.0% |
| 52w high | $7.72 |
| Market cap (USD) | $2.46B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Precigen is a clinical-stage biotechnology company that achieved its first profitable quarter in Q2 2026, driven by rapidly accelerating commercial sales of PAPZIMEOS for recurrent respiratory papillomatosis.
Rationale
The 111% analyst upside signal is reinforced by a genuine fundamental inflection—PAPZIMEOS revenue more than doubled sequentially to $53.1M, delivering actual EPS that crushed estimates by 475%, giving price targets credible earnings power to grow into.
Material risks
- 1PAPZIMEOS is a single-product revenue story serving a rare-disease niche (RRP), making the entire thesis vulnerable to any safety signal, label restriction, or competitive entrant that disrupts what is currently a near-monopoly launch.
- 2Analyst coverage is thin (only 3 analysts) with high target dispersion of 48%, meaning the 111% consensus upside figure is statistically fragile and a single downgrade or target cut could materially reprice the signal.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.